Inactivated Poliovirus Vaccine

Inactivated Poliovirus Vaccine Market Outlook

The global Inactivated Poliovirus Vaccine Market is expected to grow significantly over the forecast period, with a projected market size reaching approximately USD 5 billion by 2035, exhibiting a compound annual growth rate (CAGR) of around 8.5%. This growth can be attributed to the rising awareness regarding vaccination and the imperative need for immunization programs aimed at eradicating poliovirus. Additionally, increasing government initiatives and collaborations with global health organizations, such as the World Health Organization, play a crucial role in boosting the accessibility and availability of these vaccines across various regions. The growing incidence of vaccine-preventable diseases and the pressing need for robust public health strategies further propel the demand for inactivated poliovirus vaccines. The research and development (R&D) investments in vaccine formulations are also gaining traction, thereby contributing to the overall growth of the market.

Growth Factor of the Market

The Inactivated Poliovirus Vaccine market is primarily driven by heightened awareness regarding the importance of vaccination programs and the global commitment towards eradicating poliovirus. Various governments and health organizations are prioritizing immunization initiatives, which has led to increased budgets for vaccine procurement and distribution. Furthermore, the prevalence of poliovirus in certain regions, particularly in underdeveloped and developing countries, necessitates ongoing vaccination campaigns and supplementary immunization activities, ultimately resulting in higher demand for inactivated poliovirus vaccines. Innovations in vaccine technology that enhance efficacy and safety profiles are also contributing to market growth, as healthcare providers are more inclined to recommend advanced formulations. Additionally, the COVID-19 pandemic has underscored the importance of vaccines in public health, leading to increased funding and support for vaccine development and distribution channels.

Key Highlights of the Market

• The market is projected to reach USD 5 billion by 2035, growing at a CAGR of 8.5%.
• Government initiatives and international collaborations are enhancing vaccine accessibility.
• R&D investments are increasing, leading to innovative vaccine formulations.
• There is a growing emphasis on immunization programs in developing regions.
• The pandemic has highlighted the critical role of vaccines in public health strategies.

By Product Type

Conventional Inactivated Poliovirus Vaccine:

The conventional inactivated poliovirus vaccine has been the cornerstone of immunization strategies since its introduction. This vaccine comprises inactivated strains of the poliovirus and is effective in eliciting an immune response without causing the disease. It is typically administered in multiple doses, which ensures sustained immunity in populations. The conventional vaccine is predominant in many vaccination programs around the world, primarily due to its long-standing safety profile and proven efficacy. However, the conventional formulation may require cold chain logistics for storage and transport, which can pose challenges in resource-limited settings. Consequently, ongoing efforts are focused on optimizing distribution methods and improving access to these vaccines, especially in rural and underserved areas where polio remains a threat.

Enhanced Inactivated Poliovirus Vaccine:

The enhanced inactivated poliovirus vaccine represents an advancement over conventional formulations, designed to provide improved immunogenicity and longer-lasting protection. This vaccine includes adjuvants or novel delivery systems that enhance the immune response, reducing the number of doses required for effective immunization. The enhanced formulation is particularly beneficial in outbreak scenarios, where rapid immunization is crucial, and in populations that may have suboptimal responses to standard vaccines. As awareness of these benefits grows, healthcare providers and policymakers are increasingly adopting enhanced vaccines into their immunization protocols. Owing to its strategic advantages, the enhanced inactivated poliovirus vaccine is anticipated to capture a significant share of the market, particularly in regions with ongoing poliovirus transmission.

Novel Inactivated Poliovirus Vaccine:

The novel inactivated poliovirus vaccine is an innovative approach that utilizes cutting-edge technology to improve the safety and efficacy of poliovirus immunization. This vaccine variant is developed using modern techniques such as recombinant DNA technology, allowing for the targeted expression of poliovirus antigens, leading to a robust immune response. Clinical studies have shown promising results regarding the immunogenicity and safety of these novel vaccines, making them an attractive option for future vaccination campaigns. Their potential to be produced more efficiently and with fewer safety concerns compared to traditional vaccines positions them as a strong contender in the market. As global health organizations ramp up efforts to eradicate poliovirus, the demand for novel inactivated poliovirus vaccines is expected to increase significantly in the coming years.

By Application

Routine Immunization:

Routine immunization is a critical application of inactivated poliovirus vaccines, as it forms the backbone of public health efforts to prevent poliovirus transmission. This application is typically integrated into national immunization schedules, ensuring that children receive their vaccinations at specified ages. The routine immunization strategy is designed to maintain herd immunity within communities, reducing the likelihood of outbreaks. The systematic approach to vaccination provided by routine immunization programs allows for consistent monitoring and assessment of vaccination coverage, ensuring that the most vulnerable populations are protected. With global initiatives aiming to sustain immunization efforts amidst challenges such as vaccine hesitancy and logistical barriers, routine immunization remains a fundamental pillar in the fight against poliovirus.

Supplementary Immunization:

Supplementary immunization activities play a crucial role in addressing gaps in vaccination coverage, particularly in regions that experience periodic outbreaks of poliovirus. These targeted campaigns typically follow the identification of low immunization rates or the occurrence of poliovirus cases, aiming to rapidly increase vaccination coverage to halt transmission. The inactivated poliovirus vaccine is utilized in these campaigns to quickly immunize large populations, particularly children, who are at the highest risk of infection. By employing various strategies, including mass vaccination days and outreach initiatives, supplementary immunization has proven effective in curbing outbreaks and achieving higher levels of immunity. The global commitment to eradication efforts relies heavily on the success of supplementary immunization campaigns, making it an essential application of inactivated poliovirus vaccines.

Outbreak Response:

Outbreak response refers to the rapid deployment of inactivated poliovirus vaccines in response to confirmed cases or localized outbreaks of poliovirus. This application is critical in controlling outbreaks and preventing further transmission, particularly in areas where immunization coverage is suboptimal. The quick mobilization of resources and coordination among health authorities are essential components of an effective outbreak response. Inactivated poliovirus vaccines are strategically administered to at-risk populations, often using targeted outreach methods to ensure maximum coverage. The success of outbreak response efforts hinges on timely information sharing and collaboration among local, national, and international health organizations. Enhanced surveillance systems are crucial in identifying outbreaks early, allowing for a swift response that can effectively mitigate the impact of poliovirus transmission.

By Distribution Channel

Hospitals:

Hospitals are a primary distribution channel for inactivated poliovirus vaccines, serving as crucial points of care where vaccinations are administered to patients. With trained healthcare professionals on-site, hospitals can provide comprehensive immunization services, ensuring that individuals receive the necessary doses according to recommended schedules. Hospitals are particularly significant for the administration of inactivated poliovirus vaccines during routine immunization, as they can easily integrate vaccination services into pediatric care protocols. Additionally, hospitals are often equipped with cold chain facilities, ensuring the proper storage and handling of vaccines, thus maintaining their efficacy. The role of hospitals extends beyond just vaccination; they also play a vital part in educating parents and caregivers about the importance of immunization, ultimately contributing to higher vaccination rates in communities.

Clinics:

Clinics serve as another vital distribution channel for inactivated poliovirus vaccines, providing accessible immunization services to local populations. Many clinics are community-based, making them convenient for families seeking vaccinations for their children. These clinics often collaborate with public health organizations to implement vaccination campaigns, reaching out to underserved populations and ensuring equitable access to immunization services. The smaller, more personal setting of clinics allows healthcare providers to offer tailored advice to parents and guardians regarding vaccination schedules and safety. Furthermore, clinics can quickly adapt to fluctuating demand for vaccines, enabling them to respond effectively to local outbreaks or changes in public health guidance. Overall, the role of clinics in promoting and administering inactivated poliovirus vaccines is indispensable for achieving community-wide immunity.

Vaccination Centers:

Vaccination centers are specifically established facilities dedicated to providing immunization services, including the administration of inactivated poliovirus vaccines. These centers often operate during public health campaigns or periods of heightened vaccination demand, offering extended hours and streamlined services to cater to large numbers of individuals. The establishment of vaccination centers is particularly effective in urban areas where population density may necessitate focused immunization efforts. These centers can facilitate mass vaccination events, efficiently distributing vaccines to thousands of individuals in a short timeframe. Additionally, vaccination centers often serve as educational hubs, providing information on vaccine safety and the importance of immunization to the public. Their role in supporting national vaccination strategies is crucial for ensuring high coverage rates and controlling vaccine-preventable diseases.

Retail Pharmacies:

Retail pharmacies have emerged as an increasingly important distribution channel for inactivated poliovirus vaccines, particularly in regions where access to healthcare facilities may be limited. These pharmacies offer the convenience of receiving vaccinations during routine shopping trips, significantly enhancing the accessibility of immunization services. Many retail pharmacies have trained pharmacists who can administer vaccines, providing a valuable resource for individuals seeking to stay up-to-date on their immunizations. Retail pharmacies often run awareness campaigns to encourage parents to bring their children in for vaccinations, thereby contributing to higher vaccination rates. With the rise of health-focused retail environments, the role of pharmacies in the administration of inactivated poliovirus vaccines is likely to grow, supporting broader public health objectives.

Online Pharmacies:

Online pharmacies have gained traction as a distribution channel for inactivated poliovirus vaccines, particularly in response to the increasing demand for convenient healthcare solutions. While traditional vaccine administration requires in-person visits, online pharmacies can facilitate the ordering of vaccines, allowing healthcare providers to deliver immunization services more efficiently. Through partnerships with local healthcare professionals and clinics, online pharmacies can streamline the vaccination process, improving access for individuals and families who may face logistical challenges in reaching physical locations. Moreover, online pharmacies often leverage telehealth services to offer consultations and answer questions regarding vaccination, enhancing the overall immunization experience. As trends towards digital health solutions continue to rise, the integration of online pharmacies into the vaccination landscape is expected to expand, supporting efforts to increase vaccination uptake.

By Ingredient Type

Type 1 Poliovirus:

Type 1 poliovirus is one of the three serotypes of poliovirus targeted by inactivated poliovirus vaccines. Vaccines formulated with Type 1 poliovirus are critical in preventing poliomyelitis, as this serotype has historically caused the majority of poliovirus cases. The presence of Type 1 poliovirus in vaccines stimulates the immune system to produce antibodies, offering protection against infection. Global health initiatives focus on ensuring that Type 1 poliovirus vaccines are accessible, particularly in areas where this serotype is prevalent. Continued vaccination efforts against Type 1 poliovirus are essential for the overall goal of eradicating poliomyelitis worldwide, as resurgence of this serotype can lead to outbreaks in previously polio-free regions.

Type 2 Poliovirus:

Type 2 poliovirus is another critical serotype in the fight against poliomyelitis, and it was declared eradicated in 2015. Inactivated poliovirus vaccines containing Type 2 poliovirus are vital for ensuring that immunity remains robust, particularly in populations that may have been exposed to this serotype in the past. While Type 2 poliovirus is no longer circulating in the wild, it is still included in the vaccine formulations to prevent potential reintroduction from vaccine-derived poliovirus strains. The ongoing immunization against Type 2 poliovirus is part of comprehensive strategies to maintain global immunity levels and prevent any resurgence of this serotype. As vaccination efforts continue, monitoring and surveillance remain crucial to ensure the absence of Type 2 poliovirus and assess the need for any future adjustments to vaccination strategies.

Type 3 Poliovirus:

Type 3 poliovirus is the final serotype targeted by inactivated poliovirus vaccines, and it has been responsible for a significant number of poliomyelitis cases in the past. Although Type 3 was declared eradicated in 2019, its inclusion in the vaccine formulations remains essential to maintain a high level of immunity within populations. The persistence of Type 3 in vaccine-derived strains necessitates ongoing vaccination efforts to prevent any potential outbreaks. Vaccines containing Type 3 poliovirus play a crucial role in bolstering immunity across various demographics, especially in regions where the risk of exposure remains. Continued focus on immunization against Type 3 poliovirus is necessary to sustain the achievements of global polio eradication initiatives and prevent future cases of poliomyelitis.

By Region

The regional analysis of the Inactivated Poliovirus Vaccine Market indicates substantial variation in demand and vaccination coverage across different geographic areas. In North America, the emphasis is on maintaining high immunization rates to prevent the reintroduction of poliovirus, with vaccination programs supported by robust public health infrastructure. The market in North America is projected to grow at a CAGR of approximately 6.5%, driven by ongoing vaccination initiatives and public awareness campaigns. Europe demonstrates a similar trend, with a strong commitment to sustaining vaccination efforts to protect against poliovirus. Countries within Europe are increasingly focusing on booster vaccination strategies, contributing to a healthy market growth rate in line with the global average.

In Asia Pacific, the Inactivated Poliovirus Vaccine Market is expected to see considerable growth, with a CAGR projected at 9.5% during the forecast period. This growth is largely fueled by the high burden of polio in certain countries, necessitating urgent and widespread vaccination efforts. Efforts to eradicate poliovirus in Asia remain a priority, with significant investments being made to enhance vaccine delivery systems and increase access to immunization services. Latin America and the Middle East & Africa regions are also witnessing growth, driven by ongoing public health initiatives and supplementary immunization campaigns aimed at improving vaccination coverage and preventing poliovirus outbreaks.

Opportunities

The Inactivated Poliovirus Vaccine Market presents numerous opportunities for stakeholders looking to engage in the public health sector. With the global momentum towards eradicating poliomyelitis, there is a significant demand for innovative vaccine formulations that can enhance immunogenicity and improve distribution logistics. Companies that invest in research and development to formulate more effective and accessible vaccines will find a growing market presence. Furthermore, partnerships with governments and international health organizations can provide avenues for collaboration in vaccine procurement and distribution, particularly in underserved regions. The increasing trend towards digital health solutions also opens opportunities for innovative service delivery models, such as online pharmacies and telehealth consultations, to enhance vaccination accessibility and education.

Additionally, ongoing awareness campaigns and educational initiatives regarding the importance of vaccinations present opportunities for engagement at the community level. Public-private partnerships can be instrumental in promoting immunization and addressing vaccine hesitancy, ultimately improving vaccination rates. Moreover, as countries continue to recover from the COVID-19 pandemic, there is potential for the integration of inactivated poliovirus vaccines into broader health programs, such as maternal and child health initiatives. This integration can foster a more comprehensive approach to healthcare, ultimately benefitting the overall health of populations and supporting the goals of global immunization efforts.

Threats

The Inactivated Poliovirus Vaccine Market faces several threats that could impede its growth and effectiveness. One of the primary challenges is vaccine hesitancy, which has gained traction in recent years due to misinformation and skepticism surrounding vaccine safety. This hesitancy can result in lower vaccination rates, leading to potential outbreaks of poliovirus in communities that previously had high immunity levels. The threat of misinformation is exacerbated by social media, where unfounded fears about vaccines can spread rapidly, influencing public perception and behavior. Addressing vaccine hesitancy will require targeted communication strategies and community engagement efforts to educate the public on the benefits and safety of immunization.

Furthermore, logistical challenges related to vaccine storage and distribution, particularly in low-resource settings, pose a significant threat to effective vaccination campaigns. Inactivated poliovirus vaccines often require cold chain logistics to maintain their efficacy, and the lack of infrastructure in certain regions can hinder vaccine accessibility. Additionally, geopolitical factors, including conflicts and instability, can disrupt vaccination programs and impede efforts to reach populations in need. The emergence of vaccine-derived poliovirus strains also poses a threat, as these strains can lead to outbreaks in under-immunized communities. Overall, addressing these threats will require coordinated efforts from governments, health organizations, and communities to ensure the continued success of immunization initiatives.

Competitor Outlook

• Sanofi Pasteur
• GlaxoSmithKline (GSK)
• Merck & Co.
• Pfizer
• Novartis
• Serum Institute of India
• Bharat Biotech
• China National Pharmaceutical Group (Sinopharm)
• Valneva SE
• Instituto Butantan
• Vaccine Research Center, NIH
• Takeda Pharmaceutical Company
• Hilleman Laboratories
• Biovac
• Emergent BioSolutions

The competitive landscape of the Inactivated Poliovirus Vaccine Market is characterized by a diverse array of players, including both established pharmaceutical companies and emerging biotechnology firms. Leading companies like Sanofi Pasteur and GlaxoSmithKline have long histories of vaccine development and extensive global distribution networks, positioning them as key contributors to public health initiatives. These companies invest heavily in R&D to innovate and enhance existing vaccine formulations, focusing on improving immunogenicity and safety profiles. Furthermore, they actively collaborate with governmental and international health organizations to facilitate vaccine procurement and distribution, particularly in regions with high disease prevalence.

Emerging players, such as Serum Institute of India and Bharat Biotech, are also making significant strides in the Inactivated Poliovirus Vaccine Market. These companies leverage their local manufacturing capabilities and expertise to develop cost-effective vaccines that cater to the needs of developing nations. Their ability to produce vaccines at scale while maintaining affordability enables them to play a crucial role in global immunization efforts. Additionally, companies like China National Pharmaceutical Group and Takeda are expanding their portfolios to include inactivated poliovirus vaccines, further enhancing the market's competitiveness. The increasing involvement of biotechnology firms underscores the importance of innovation in the vaccine space, leading to novel formulations and improved delivery methods.

As the market continues to evolve, companies are expected to focus on strengthening their supply chains and distribution networks to ensure timely access to vaccines, particularly in areas experiencing vaccine shortages. The ongoing global commitment to eradicating poliovirus also presents opportunities for partnerships and collaborations that can enhance vaccine delivery mechanisms. Overall, the competitive outlook for the Inactivated Poliovirus Vaccine Market is promising, with numerous players actively contributing to the goal of achieving global health security through effective immunization strategies.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Biovac
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Pfizer
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Novartis
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Valneva SE
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Merck & Co.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Bharat Biotech
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Sanofi Pasteur
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Instituto Butantan
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Emergent BioSolutions
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 GlaxoSmithKline (GSK)
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Hilleman Laboratories
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Serum Institute of India
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Vaccine Research Center, NIH
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Takeda Pharmaceutical Company
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 China National Pharmaceutical Group (Sinopharm)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Inactivated Poliovirus Vaccine Market, By Application
    • 6.1.1 Routine Immunization
    • 6.1.2 Supplementary Immunization
    • 6.1.3 Outbreak Response
  • 6.2 Inactivated Poliovirus Vaccine Market, By Product Type
    • 6.2.1 Conventional Inactivated Poliovirus Vaccine
    • 6.2.2 Enhanced Inactivated Poliovirus Vaccine
    • 6.2.3 Novel Inactivated Poliovirus Vaccine
  • 6.3 Inactivated Poliovirus Vaccine Market, By Ingredient Type
    • 6.3.1 Type 1 Poliovirus
    • 6.3.2 Type 2 Poliovirus
    • 6.3.3 Type 3 Poliovirus
  • 6.4 Inactivated Poliovirus Vaccine Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Clinics
    • 6.4.3 Vaccination Centers
    • 6.4.4 Retail Pharmacies
    • 6.4.5 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Inactivated Poliovirus Vaccine Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Inactivated Poliovirus Vaccine market is categorized based on

By Product Type

• Conventional Inactivated Poliovirus Vaccine
• Enhanced Inactivated Poliovirus Vaccine
• Novel Inactivated Poliovirus Vaccine

By Application

• Routine Immunization
• Supplementary Immunization
• Outbreak Response

By Distribution Channel

• Hospitals
• Clinics
• Vaccination Centers
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Type 1 Poliovirus
• Type 2 Poliovirus
• Type 3 Poliovirus

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Sanofi Pasteur
• GlaxoSmithKline (GSK)
• Merck & Co.
• Pfizer
• Novartis
• Serum Institute of India
• Bharat Biotech
• China National Pharmaceutical Group (Sinopharm)
• Valneva SE
• Instituto Butantan
• Vaccine Research Center, NIH
• Takeda Pharmaceutical Company
• Hilleman Laboratories
• Biovac
• Emergent BioSolutions